Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Related Questions
Can serological markers such as KL-6, MMP-7, and anti-CarP be used to monitor interstitial lung disease in patients with rheumatoid arthritis in clinical practice?
How do you taper corticotropin injections (Acthar) in patients with rheumatologic disease?
How would you approach using the new vagus nerve stimulator for patients with RA?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
Have you seen synovitis (even if subtle) with aromatase inhibitor musculoskeletal syndrome?
How do you assess the potential role of obesity in driving inflammatory joint symptoms?
In what clinical situations do you consider azathioprine for treatment of inflammatory arthritis?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
Would you stop methotrexate or leflunomide if MCV increases after starting the medication with no other parameters of anemia or leukopenia?
How do you approach management of a patient with multiple lung nodules and low titer +CCP but no active joint symptoms suggestive of RA?
